Osimertinib in Combination With Navitoclax in EGFR-Mutant NSCLC Following Resistance to Initial EGFR Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase IB Study of Osimertinib in Combination With Navitoclax in EGFR-Mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
Clin. Cancer Res 2020 Dec 29;[EPub Ahead of Print], EM Bertino, RD Gentzler, SE Clifford, JM Kolesar, A Muzikansky, EB Haura, Z Piotrowska, DR Camidge, TE Stinchcombe, CL Hann, J Malhotra, LC Villaruz, CP Paweletz, CJ Lau, LM Sholl, N Takebe, JA Moscow, GI Shapiro, PA Janne, GR OxnardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.